Diagnostics News and Research

RSS

RiboMed releases multi-marker methylation prognostic test for glioma

RiboMed Clinical Services Laboratory (RCSL), a CLIA-certified subsidiary of RiboMed Biotechnologies, today announced the release of a multi-marker methylation prognostic test for grading gliomas, the most common type of brain cancer.

12 Apr 2012

Quest Diagnostics receives FDA clearance for Simplexa C. difficile Universal Direct test

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M Integrated Cycler.

From Quest Diagnostics 12 Apr 2012

Preliminary results from GE Healthcare’s flutemetamol Phase 3 studies on AD

GE Healthcare today announced the preliminary results of two Phase 3 studies of its investigational PET amyloid imaging agent, [18F]flutemetamol, where both studies met their primary endpoints. One study, in terminally ill patients who agreed to undergo brain autopsy, showed strong concordance between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

12 Apr 2012

ST2 more specific than BNP for heart failure diagnosis

Critical Diagnostics today announced publication in the latest issue of the Journal of Heart Failure results of a study involving 995 patients who presented to the emergency room (ER) with chest pain. The study concluded that in this undifferentiated, symptomatic patient population ST2 was more specific for acute heart failure than BNP and that ST2 is independently predictive of future death and/or heart failure and has incremental utility in combination with BNP.

12 Apr 2012

SomaLogic, HUNT Biosciences partner to advance clinical use of cardiovascular biomarkers

HUNT Biosciences and SomaLogic, Inc., today announced a new collaboration to advance the clinical use of protein biomarkers, with an initial focus on the validation of biomarkers for the prediction of cardiovascular events such as strokes, heart attacks, and heart failure.

11 Apr 2012

CLYD gene serves as crucial negative regulator in pulmonary fibrosis

An international team of researchers led by Georgia State University scientists have found a key component in the pathological process of pulmonary fibrosis, a fatal disease for which there is currently no cure.

11 Apr 2012

Siemens announces integrated imaging solution for detection of amyloid plaques

Siemens Healthcare is the first company worldwide to announce a complete integrated diagnostic imaging solution proposed for the detection of amyloid plaques — one of the necessary pathological features of Alzheimer's disease— in the living brain.

From Siemens Healthineers 11 Apr 2012

Boston Scientific receives European CE Mark approval for INGENIO family of pacemakers

Boston Scientific Corporation announces CE Mark approval and European market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers.

11 Apr 2012

Bimodal genes can define molecular subtypes of ovarian cancer

Scientists from Duke University Medical Center have determined that genes acting as molecular "on/off" switches can define clinically relevant molecular subtypes of ovarian cancer, providing ideal potential targets for use in clinical prognostic and diagnostic testing.

9 Apr 2012

Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

9 Apr 2012

Nuron Biotech licenses DNA amyloid beta 42 vaccine for AD

Nuron Biotech, Inc. today announced it has licensed from VITRUVIAN BioMedical, Inc. a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for Alzheimer's disease (AD).

9 Apr 2012

ISS recommends Illumina shareholders to vote against Roche's nominees

Roche released the following statement in response to a report issued by Institutional Shareholder Services recommending that shareholders of Illumina, Inc. vote against the election of Roche's independent director nominees to Illumina's Board of Directors.

From Illumina, Inc. 7 Apr 2012

Antibiotics may have absolutely no effect within a few decades

The increased resistance of bacteria to antibiotics is a global problem. Antibiotics are increasingly less effective. Microbiologist Dr. John Hays of Erasmus MC in Rotterdam is sounding the alarm: "The problem is so dire that within a few decades antibiotics will have absolutely no effect".

6 Apr 2012

Web-based worksite health promotion program minimizes absenteeism

Workers participating in a "comprehensive" workplace promotion program had a one-fifth reduction in absenteeism during the first year, reports a study in the April Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

6 Apr 2012

Ameritox, Ridge Diagnostics partner to develop MDDScore test

Ridge Diagnostics, Inc., a neurodiagnostic company, announced today it has entered into an exclusive agreement with Ameritox, Ltd., a leader in medication monitoring, for the license rights to its proprietary developmental blood test MDDScore, a multiple biomarker analysis for Major Depressive Disorder (MDD) for primary care and pain physicians.

6 Apr 2012

New NewYork-Presbyterian autism center to open in early 2013

NewYork-Presbyterian Hospital, along with its affiliated medical schools Weill Cornell Medical College and Columbia University College of Physicians and Surgeons, today celebrated the start of construction on the new Center for Autism and the Developing Brain at the Hospital's Westchester campus in White Plains.

5 Apr 2012

Applied BioCode receives U.S. patent titled, ‘Light Transmitted Assay Beads’

Applied BioCode, Inc. today announced that the United States Patent and Trademark Office has issued US Patent #8,148,139 "Light Transmitted Assay Beads," describing the method of use and manufacturing of its Barcoded Magnetic Beads (BMB) products.

5 Apr 2012

Results from Abbott’s multiple interferon-free Phase 2 HCV studies to be presented at ILC 2012

Abbott will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.

5 Apr 2012

CHD8, SNC2A and KATNAL2 gene mutations lead to ASDs

Mutations in three new genes have been linked to autism, according to new studies including one with investigators at Mount Sinai School of Medicine. All three studies include lead investigators of the Autism Sequencing Consortium.

5 Apr 2012

Navidea announces FDA extension of Lymphoseek PDUFA date by three months

Navidea Biopharmaceuticals, Inc. today announced that yesterday it received notification from the United States Food and Drug Administration (FDA) that the Prescription Drug User Fee Act (PDUFA) date for 99m-Tc-Tilmanocept, has been modified to September 10, 2012, a 90-day extension from the initial PDUFA date of June 10th.

4 Apr 2012